merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>safety risks including brain swelling and bleeding</answer>
<question_number>2</question_number>
<answer>might discourage patients from participating in trials for potentially better treatments</answer>
<question_number>3</question_number>
<answer>no correlation</answer>
<question_number>4</question_number>
<answer>raises concerns about its safety</answer>
<question_number>5</question_number>
<answer>expectation that patients can stop treatment after amyloid clearance</answer>
<question_number>6</question_number>
<answer>discourage patients from participating in other clinical trials</answer>
<question_number>7</question_number>
<answer>patients can stop treatment once amyloid is cleared</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>intermediate tau levels showed slower decline with donanemab</answer>